Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,350,276 | Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA In force · High confidence | Celcuity Inc. | In force | High confidence | ||
| Application 19/229,722 | Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA Pending Not granted | Celcuity Inc. | Pending | Not granted | not computed | |
| Application 19/539,411 | Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA Pending Not granted | Celcuity Inc. | Pending | Not granted | not computed | |
| Application 19/692,517 | Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA Pending Not granted | Celcuity, Inc. | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Celcuity Inc..
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.